Gynaecology ·
Estradiol in Women’s Health — What Estrafleg Does, Who Needs It and Why It Matters
Oestrogen is at the centre of everything — fertility, menopause, bone health, mood and the lining of the uterus itself. When its levels fall, the effects are felt across the entire body. Estrafleg, Quinek Life Sciences’ Estradiol Hemihydrate 2mg formulation, is designed to restore what the body is missing — precisely and reliably.
The Role of Oestrogen in a Woman’s Body
Oestrogen is not just a reproductive hormone. It is one of the most important regulatory chemicals in the female body — responsible for maintaining the uterine lining, supporting bone density, regulating cholesterol, protecting cardiovascular health, influencing mood and cognition, and maintaining the health of skin and mucosal tissues throughout the body.
Estradiol — the most biologically active form of oestrogen — is produced primarily by the ovaries during the reproductive years. When ovarian function declines, whether through natural menopause, surgical removal, premature ovarian insufficiency, or during a medically controlled IVF cycle, estradiol levels fall. The consequences range from missed embryo implantation during fertility treatment to debilitating menopausal symptoms and accelerated bone loss in older women.
Estradiol replacement therapy — through well-formulated, bioavailable preparations — is how these consequences are addressed. Estrafleg, Quinek Life Sciences’ estradiol formulation, is available in two forms: as a 2mg oral tablet (Estradiol Hemihydrate) and as a 0.06% topical gel — offering specialists the flexibility to choose the right route for each patient’s clinical need.
“Successful embryo implantation depends on endometrial thickness. Estradiol hemihydrate has been shown in Indian clinical studies to achieve a mean endometrial thickness of 9.57mm — well above the 7mm threshold for successful transfer.”
— Banker et al., International Journal of Reproductive Medicine, 2021 (Nova IVF, India — 2,529 patients)
What Is Estradiol Hemihydrate — and How Is It Different?
Estradiol is available in several pharmaceutical forms — Estradiol Valerate, Estradiol Hemihydrate and micronised Estradiol are the most commonly used. Estradiol Hemihydrate is the form used in Estrafleg. It is a crystalline salt form of estradiol with excellent oral bioavailability — absorbed efficiently through the gastrointestinal tract and converted directly to 17β-estradiol (the biologically active form) in the body.
A large-scale retrospective study conducted at Nova IVF Fertility, Ahmedabad — involving 2,529 Indian women — directly compared Estradiol Hemihydrate with Estradiol Valerate in HRT-FET (hormone replacement therapy — frozen embryo transfer) cycles. The results showed that Estradiol Hemihydrate achieved a mean endometrial thickness of 9.57mm compared to 9.25mm with Estradiol Valerate, with no significant differences in clinical pregnancy rate, abortion rate or live birth rate. The clinical conclusion: Estradiol Hemihydrate is at least as effective as the established standard — and may offer marginal endometrial advantage.
Clinical Indications for Estrafleg
IVF — Endometrial Preparation for Embryo Transfer
The most critical use of Estrafleg in assisted reproduction. Before a frozen embryo transfer (FET), the endometrium must be adequately prepared and thickened to support implantation. Estrafleg oral tablets are prescribed from the start of the cycle, building the uterine lining to the optimal thickness of 8mm or above — the threshold at which implantation success rates are significantly higher. It may be used orally, or vaginally for enhanced local absorption in resistant cases.
Hormone Replacement Therapy (HRT) — Menopause Management
Menopause brings a sharp and sustained fall in estradiol. Hot flushes, night sweats, vaginal dryness, disturbed sleep, mood changes, joint pain and cognitive difficulties are all oestrogen-withdrawal symptoms. Estrafleg restores estradiol to physiological levels — providing sustained relief from these symptoms and protecting against the long-term risks of oestrogen deficiency including osteoporosis and cardiovascular decline.
Premature Ovarian Insufficiency (POI)
When the ovaries stop functioning before the age of 40, women enter a state of oestrogen deficiency far earlier than the natural menopausal timeline. POI carries significant risks — accelerated bone loss, cardiovascular risk and fertility loss. Estrafleg replaces the oestrogen the ovaries are no longer producing and is typically continued until the natural age of menopause.
Surgical Menopause
Women who undergo bilateral oophorectomy (surgical removal of the ovaries) experience an abrupt cessation of oestrogen — more sudden and severe than natural menopause. Estrogen replacement is started immediately post-surgery to prevent acute oestrogen withdrawal and is maintained to protect long-term health outcomes.
Amenorrhoea and Hormonal Cycle Disorders
In women with secondary amenorrhoea (absent periods due to hormonal imbalance), Estrafleg is used as part of a sequential hormone replacement protocol — restoring the oestrogen phase of the menstrual cycle and facilitating withdrawal bleeding when combined with a progestogen.
Osteoporosis Prevention
Oestrogen plays a crucial role in maintaining bone mineral density. Post-menopausal women who do not receive oestrogen replacement experience accelerated bone loss — significantly increasing fracture risk. Estrafleg, as part of a monitored HRT programme, provides effective oestrogen-mediated bone protection in menopausal women who are not suitable for or have not responded to bisphosphonate therapy.
Estrafleg Gel 0.06% — Transdermal Estradiol for Targeted Delivery
The Estrafleg gel formulation provides Estradiol at 0.06% concentration for transdermal (through the skin) delivery. Applied daily to the arms, shoulders or thighs, the gel delivers estradiol directly into the bloodstream through the skin — bypassing first-pass metabolism in the liver entirely.
Advantages of the Transdermal Route
By avoiding the liver on first pass, transdermal estradiol does not stimulate hepatic protein synthesis — meaning it has a more favourable impact on coagulation factors and a lower associated thromboembolic risk compared to oral oestrogen. For women with risk factors for blood clots, or those who experience nausea with oral tablets, the gel offers a clinically meaningful alternative.
When the Gel Is Preferred
Estrafleg Gel is particularly prescribed in women with a history of deep vein thrombosis or cardiovascular risk factors, women who are not absorbing oral estradiol adequately, women with significant gastrointestinal side effects from oral therapy, and as adjunct to oral therapy in IVF patients with suboptimal endometrial response — where local vaginal estradiol is not sufficient.
Important Clinical Considerations for Prescribers
Always co-prescribe a progestogen in women with an intact uterus using systemic estradiol. Unopposed oestrogen stimulates the endometrium and increases the risk of endometrial hyperplasia. A progestogen (such as Dydrogesterone or Micronised Progesterone) should always be included in any HRT regime for a woman who has not had a hysterectomy.
Monitor estradiol levels and endometrial thickness regularly during IVF endometrial preparation cycles — dose adjustments may be needed based on individual response.
Do not stop abruptly in HRT patients — gradual tapering is recommended when discontinuing long-term oestrogen therapy to avoid withdrawal symptoms.
Quinek Life Sciences — Gynaecology Segment
Estrafleg — Precision Estradiol Therapy from a WHO-GMP Certified Manufacturer
Estrafleg is Quinek Life Sciences’ dedicated estradiol formulation — manufactured at our WHO-GMP, GLP and ISO certified facilities and developed for the precise clinical demands of IVF specialists, gynaecologists and menopause practitioners across India.
Available in two presentations — the 2mg oral tablet and the 0.06% transdermal gel — Estrafleg gives prescribers the flexibility to tailor oestrogen delivery to each patient’s clinical profile, route preference and tolerance. Both formulations are manufactured to exacting quality standards with consistent potency and bioavailability in every batch.
If you are a gynaecologist, IVF specialist, menopause practitioner or pharmaceutical distributor looking to partner with a trusted gynaecology pharma company — Quinek Life Sciences would like to speak with you.
Oestrogen Matters — at Every Stage of a Woman’s Life
From the endometrial preparation that allows an embryo to implant, to the hormone replacement that protects a menopausal woman’s bones and cardiovascular health decades later — estradiol is present at every critical stage of a woman’s hormonal life. When the body can no longer produce it at the required levels, the right pharmaceutical formulation makes all the difference.
Estrafleg — Estradiol Hemihydrate 2mg and Estradiol Gel 0.06% — from Quinek Life Sciences, is designed to meet that need with the precision, quality and consistency that women’s health demands.
Medical Disclaimer: This article is for healthcare professional and educational reference only. Estradiol therapy must be prescribed and monitored by a qualified gynaecologist or reproductive medicine specialist. All clinical decisions should be based on individual patient assessment.
Sources: Banker et al., International Journal of Reproductive Medicine (2021) · Cureus (2026) · Apollo Pharmacy Clinical Reference · CDSCO Prescribing Information — Tacrolimus · Quinek Life Sciences Gynaecology Segment
